Holen Sie sich die Stockscreener-App
167.33
0.80%
1.33
Vorhandelsmarkt:
165.79
-1.54
-0.92%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$166.00
Offen:
$166.12
24-Stunden-Volumen:
1.14M
Relative Volume:
1.15
Marktkapitalisierung:
$18.42B
Einnahmen:
$9.54B
Nettoeinkommen (Verlust:
$841.00M
KGV:
22.49
EPS:
7.44
Netto-Cashflow:
$1.02B
1W Leistung:
+0.13%
1M Leistung:
-2.46%
6M Leistung:
+8.09%
1J Leistung:
+25.71%
1-Tages-Spanne:
$165.10
$167.83
1-Wochen-Bereich:
$164.60
$168.62
52-Wochen-Spanne:
$125.42
$178.87
Quest Diagnostics Inc Stock (DGX) Company Profile
Firmenname
Quest Diagnostics Inc
Sektor
Branche
Telefon
(973) 520-2700
Adresse
500 PLAZA DRIVE, SECAUCUS
Vergleichen Sie DGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
167.33 | 18.42B | 9.54B | 841.00M | 1.02B | 7.44 |
|
TMO
Thermo Fisher Scientific Inc
|
500.16 | 196.14B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
205.85 | 150.17B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
415.87 | 34.36B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
116.69 | 33.28B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
177.39 | 31.62B | 15.41B | 1.37B | 2.11B | 7.50 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-01-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | Jefferies | Buy |
| 2024-10-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Fortgesetzt | Evercore ISI | In-line |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-02-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-29 | Eingeleitet | Piper Sandler | Neutral |
| 2023-05-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-23 | Eingeleitet | Evercore ISI | In-line |
| 2022-11-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-23 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-02 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-28 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-03-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Hochstufung | Argus | Hold → Buy |
| 2020-07-29 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-09 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-04-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2019-04-02 | Hochstufung | Jefferies | Hold → Buy |
| 2019-03-18 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-01-31 | Herabstufung | Argus | Buy → Hold |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Quest Diagnostics Inc Aktie (DGX) Neueste Nachrichten
Is Quest Diagnostics Stock Outperforming the S&P 500? - MSN
SVP for Diagnostic Services Plewman Patrick covered exercise/tax liability with 162 shares, decreasing direct ownership by 0.77% to 20,988 units (SEC Form 4) - Quantisnow
Is Quest Diagnostics Stock Worth Holding Onto Right Now? - MSN
Nephron Research Downgrades Quest Diagnostics to Hold From Buy, $184 Price Target - Marketscreener.com
Is Quest Diagnostics Stock Outperforming The S&P 500? - Barchart
Truist maintains hold on Quest Diagnostics stock, $182 target By Investing.com - Investing.com Australia
Quest Diagnostics (DGX) and Google Cloud to Transform Healthcare Data with AI - Insider Monkey
DGX Stock Set to Benefit From New Google Cloud Partnership - MSN
Top 8 AI News Updates Investors Shouldn’t Miss - Insider Monkey
What 9 Analyst Ratings Have To Say About Quest Diagnostics - Benzinga
Earnings Summary: Quest Diagnostics (DGX) reaffirms FY25 guidance - AlphaStreet
Baird Adjusts Price Target on Quest Diagnostics to $191 From $190, Keeps Outperform Rating - Marketscreener.com
Quest Diagnostics' (NYSE:DGX) Dividend Will Be Increased To $0.80 - Yahoo Finance
Quest Diagnostics SVP Michael Prevoznik sells $789,310 in stock - Investing.com
Quest Diagnostics SVP Michael Prevoznik sells $789,310 in stock By Investing.com - Investing.com Canada
Quest Diagnostics falls on Q1 outlook headwinds, reaffirms FY guidance - MSN
Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight - TradingView
Quest Diagnostics (DGX) Unveils Strategic Plans at Investor Day - GuruFocus.com
Quest Diagnostics stock falls on Q1 headwinds (DGX:NYSE) - Seeking Alpha
Quest Diagnostics to Highlight Strategic Priorities to Drive Sustainable Growth and Deliver Long-term Shareholder Value at 2025 Investor Day - Quantisnow
Quest Diagnostics projects steady growth beyond 2025 - Investing.com India
Quest Diagnostics Lowers Q1 Outlook, Reaffirms 2025 Guidance -March 19, 2025 at 08:42 am EDT - Marketscreener.com
Quest Diagnostics to Highlight Strategic Priorities to Drive Sustainable Growth and Deliver Long-term Shareholder Value at 2025 Investor Day – Company AnnouncementFT.com - Financial Times
Quest Diagnostics (NYSE:DGX) Leverages Google Cloud AI For Enhanced Patient Experience - Simply Wall St
Quest Diagnostics Revolutionizes Lab Testing With Google Cloud AI Partnership - StockTitan
Baird Adjusts Price Target on Quest Diagnostics to $190 From $189, Maintains Outperform Rating - Marketscreener.com
Quest Diagnostics Reports Third Quarter 2023 Financial Results; Updates Guidance for Full Year 2023 - GuruFocus.com
Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking Quest (NYSE:DGX) - Barchart
Quest Diagnostics Incorporated (NYSE:DGX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
SBI Securities Co. Ltd. Takes Position in Quest Diagnostics Incorporated (NYSE:DGX) - Defense World
Blood Cancer Diagnostics Market Analysis Report 2025-2030, with Quest Diagnostics, Illumina, InVivoScribe, Asuragen, Danaher, Sequenta, SkylineDx, Bio-Rad Laboratories, Alercell & Sophia Genetics - Yahoo Finance
Catherine T. Doherty Sells 5,370 Shares of Quest Diagnostics Incorporated (NYSE:DGX) Stock - Defense World
Quest Diagnostics EVP Catherine Doherty sells $935,078 in stock By Investing.com - Investing.com Australia
Mutual of America Capital Management LLC Decreases Stake in Quest Diagnostics Incorporated (NYSE:DGX) - Defense World
Quest Diagnostics EVP Catherine Doherty sells $935,078 in stock - Investing.com India
Quest Diagnostics, Inc. to Host Earnings Call - ACCESS Newswire
Citigroup Downgrades Quest Diagnostics (NYSE:DGX) to Neutral - Defense World
Quest Diagnostics EVP sells $125,865 in stock - Investing.com
Quest Diagnostics EVP sells $125,865 in stock By Investing.com - Investing.com South Africa
SVP, Clinical Solutions Kuppusamy Karthik covered exercise/tax liability with 2,871 shares and was granted 4,434 shares, increasing direct ownership by 14% to 13,119 units (SEC Form 4) - Quantisnow
Labcorp Gains Citi Upgrade While Quest Diagnostics Faces Downgrade On Margin Concerns — Retail Sentiment Mixed - MSN
Quest Diagnostics Incorporated : Your health comes first -March 04, 2025 at 10:54 pm EST - Marketscreener.com
The Analyst Verdict: Quest Diagnostics In The Eyes Of 11 Experts - Benzinga
This Teleflex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Citigroup Downgrades Quest Diagnostics to Neutral From Buy, Price Target is $185 -March 04, 2025 at 05:37 am EST - Marketscreener.com
Quest Diagnostics Stock Hits All-Time High at $176.53 By Investing.com - Investing.com Canada
Quest Diagnostics Stock Jumps 38% in a Year: What's Behind the Surge? - Nasdaq
Finanzdaten der Quest Diagnostics Inc-Aktie (DGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):